These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37052498)

  • 1. CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.
    Hu X; Dong R; Huang S; Zeng Y; Zhan W; Gao X; Tian D; Peng J; Xu J; Wang T; Zhang Y; Wang X; Zhang X; Liu J; Guang B; Yang T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170422. PubMed ID: 37052498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A High-Carbohydrate Diet Prolongs Dysbiosis and Clostridioides difficile Carriage and Increases Delayed Mortality in a Hamster Model of Infection.
    Bhute SS; Mefferd CC; Phan JR; Ahmed M; Fox-King AE; Alarcia S; Villarama JV; Abel-Santos E; Hedlund BP
    Microbiol Spectr; 2022 Aug; 10(4):e0180421. PubMed ID: 35708337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
    Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
    Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Activity of Tannic Acid
    Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
    Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The
    Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
    Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2021 Mar; 11(1):7093. PubMed ID: 33782498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.
    Phan JR; Do DM; Truong MC; Ngo C; Phan JH; Sharma SK; Schilke A; Mefferd CC; Villarama JV; Lai D; Consul A; Hedlund BP; Firestine SM; Abel-Santos E
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0143521. PubMed ID: 34780262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse relapse model of Clostridium difficile infection.
    Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
    Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of live biotherapeutics against
    Zhang Y; Saint Fleur A; Feng H
    Gut Microbes; 2022; 14(1):2052698. PubMed ID: 35319337
    [No Abstract]   [Full Text] [Related]  

  • 14. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
    Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
    Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
    Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Dureja C; Rutherford JT; Pavel FB; Norseeda K; Prah I; Sun D; Hevener KE; Hurdle JG
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0122223. PubMed ID: 38265216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.